RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SinoMab BioScience Stock

SinoMab BioScience ROE 2024

SinoMab BioScience ROE

-0.82

Ticker

3681.HK

ISIN

HK0000544194

In 2024, SinoMab BioScience's return on equity (ROE) was -0.82, a 47.49% increase from the -0.56 ROE in the previous year.

SinoMab BioScience Aktienanalyse

What does SinoMab BioScience do?

SinoMab BioScience Ltd is a Chinese biotechnology company specializing in the research, development, and commercial production of innovative biopharmaceutical products. The company was founded in 2001 and is based in Hong Kong. The company's business model focuses on the development of antibody-based therapies for the treatment of cancer and inflammatory diseases. SinoMab BioScience Ltd collaborates closely with leading biopharmaceutical companies, academic institutions, and research facilities worldwide to develop therapeutics that have the potential to improve patients' lives. The company operates in various sectors, including research and development, production, and distribution of biopharmaceutical products. SinoMab also has its own research and development department dedicated to the discovery and development of antibodies. The company aims to build a pipeline of innovative products that address a wide range of medical needs. Currently, SinoMab BioScience Ltd has a range of product candidates in clinical development targeting the treatment of cancer and inflammatory diseases. One of the key products is the antibody preparation SMM-114, used for the treatment of patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma and represents one of the most common cancers in adults. SMM-114 actively inhibits the proliferation of tumor cells by blocking the protein CXCR4, which is expressed on the surface of cancer cells. Another important product candidate of the company is SMAB022, a monoclonal antibody for the treatment of patients with cutaneous squamous cell carcinoma. This product binds to the Epidermal Growth Factor Receptor (EGFR) protein on the surface of cancer cells and inhibits their proliferation. SinoMab BioScience Ltd also has a manufacturing and distribution department for biopharmaceutical products. The company has a GMP-compliant production facility and offers services such as process development, production and purification procedures, stabilization, and formulation of biopharmaceuticals. In addition, SinoMab BioScience Ltd has developed its own in vitro diagnostic (IVD) test for the detection of human papillomavirus (HPV). This disease is one of the most common sexually transmitted infections and is a serious health problem. The HPV IVD is an innovative test system that enables rapid, accurate, and reliable identification of HPV infections. Research and development is highly valued by the company, and it has established its own R&D department consisting of experienced scientists and engineers. This department focuses on the discovery and development of novel biopharmaceutical products and collaborates closely with academic institutions and research facilities. Furthermore, SinoMab BioScience Ltd has formed partnerships with other leading biopharmaceutical companies to collaborate in exploring and harnessing the potential of antibodies for the treatment of diseases. In conclusion, SinoMab BioScience Ltd is an innovative biotechnology company specializing in the development of novel biopharmaceutical therapies for the treatment of cancer and inflammatory diseases. The company has a strong research and development expertise and has built a pipeline of product candidates with the potential to improve patients' lives. With its wide range of products and services in the manufacturing and distribution of biopharmaceuticals, SinoMab BioScience Ltd has established a strong position in the market. SinoMab BioScience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding SinoMab BioScience's Return on Equity (ROE)

SinoMab BioScience's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing SinoMab BioScience's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

SinoMab BioScience's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in SinoMab BioScience’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about SinoMab BioScience stock

What is the ROE (Return on Equity) of SinoMab BioScience this year?

The ROE of SinoMab BioScience this year is -0.82 undefined.

How has the Return on Equity (ROE) of SinoMab BioScience developed compared to the previous year?

The ROE of SinoMab BioScience has increased by 47.49% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of SinoMab BioScience?

A high ROE indicates that SinoMab BioScience generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of SinoMab BioScience?

A low ROE can indicate that SinoMab BioScience is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of SinoMab BioScience affect the company?

A change in ROE (Return on Equity) of SinoMab BioScience can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of SinoMab BioScience?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of SinoMab BioScience?

Some factors that can influence SinoMab BioScience's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does SinoMab BioScience pay?

Over the past 12 months, SinoMab BioScience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SinoMab BioScience is expected to pay a dividend of 0 CNY.

What is the dividend yield of SinoMab BioScience?

The current dividend yield of SinoMab BioScience is .

When does SinoMab BioScience pay dividends?

SinoMab BioScience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SinoMab BioScience?

SinoMab BioScience paid dividends every year for the past 0 years.

What is the dividend of SinoMab BioScience?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is SinoMab BioScience located?

SinoMab BioScience is assigned to the 'Health' sector.

Wann musste ich die Aktien von SinoMab BioScience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SinoMab BioScience from 7/11/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 7/11/2024.

When did SinoMab BioScience pay the last dividend?

The last dividend was paid out on 7/11/2024.

What was the dividend of SinoMab BioScience in the year 2023?

In the year 2023, SinoMab BioScience distributed 0 CNY as dividends.

In which currency does SinoMab BioScience pay out the dividend?

The dividends of SinoMab BioScience are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SinoMab BioScience

Our stock analysis for SinoMab BioScience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SinoMab BioScience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.